Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma

Several studies have suggested that hematopoietic stem cell transplantation (HSCT) might provide a cure for primary cutaneous aggressive epidermotropic cytotoxic CD8-positive T-cell lymphoma (CD8+ PCAETL). We summarize published literature on this disease and present outcomes of 8 patients with CD8+ PCAETL treated at our institution. In our experience, allogeneic HSCT and the novel agents brentuximab and pralatrexate show substantial activity against this disease.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Benoit M. Cyrenne, Juliet Fraser Gibson, Antonio Subtil, Michael Girardi, Iris Isufi, Stuart Seropian, Francine Foss Tags: Original Study Source Type: research